Search
for
Sort by
Research 31–60 of 1000+
- Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
- Management of Toxicities of Targeted Therapies
- Drug-induced acne
- Cutaneous side-effects of EGFR inhibitors and their management.
- Acne
- Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice
- Abnormal hair growth in patients (pts) with metastatic colorectal cancer (mCRC) treated with the anti-epidermal growth factor receptor (EGFr) monoclonal antibody (mAb) panitumumab (Pmab)
- Cutaneous Reactions to Drugs
- The Cutaneous Epidermal Growth Factor Network: Can it be Translated Clinically to Stimulate Hair Growth?
- Tyrosine Kinase Inhibitors against Cancer: Their Safety in 216 Moroccan Patients
- “PRIDE” Complex
- Chemotherapy and the Skin: Understanding Dermatologic Side Effects
- Dermatologic Side Effects of Systemic Targeted Anticancer Therapy
- EGFR inhibitor-induced folliculitis decalvans: a case series and management guidelines
- Fatal Toxic Epidermal Necrolysis Associated With Cetuximab in a Patient With Colon Cancer
- The role of dermocosmetics in the management of cancer-related skin toxicities: international expert consensus
- Neutralization of IL-8 Prevents the Induction of Dermatologic Adverse Events Associated with the Inhibition of Epidermal Growth Factor Receptor
- Target-Adverse Events and Fear of Cancer Progression, Anxiety, and Depression in Patients with Advanced Non-Small Cell Lung Cancer
- Potential Use of Spin Traps to Control ROS in Antipollution Cosmetics—A Review
- Erlotinib-induced trichomegaly of eyelashes in lung cancer treatment: Epidermal growth factor receptor inhibitor side effect
- Treatment of Cultured Sebocytes with an EGFR Inhibitor Does Not Lead to Significant Upregulation of Inflammatory Biomarkers
- Novel acquisitions on the immunoprotective roles of the EGF receptor in the skin
- Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment
- Successful treatment of epidermal growth factor receptor inhibitor–induced alopecia with doxycycline
- Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody–drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology
- Spotlight commentary: Navigating the cutaneous side effects of chemotherapy
- Dermatologic adverse events associated with afatinib: an oral ErbB family blocker
- Drug eruptions in dermatology
- Cutaneous Lesions in the Rat Following Administration of an Irreversible Inhibitor of erbB Receptors, Including the Epidermal Growth Factor Receptor
- EGFR Inhibitors and Cutaneous Complications: A Practical Approach to Management